Tuesday, July 21, 2026

China’s Cheap AI Shock

Plus: ‘The Odyssey’ has the masses voyaging back to movie theaters. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌
 
The Daily Upside home
July 21, 2026

 

Good morning and happy Tuesday.

Who are you calling overcaffeinated? Drinking up to five cups of coffee per day appears to be linked to a lower risk of stroke, diabetes, heart failure and other cardiovascular conditions, according to a new scientific statement by the American Heart Association. It says the sweet spot for consumption is two to four 8-ounce cups of joe per day.

Not all javas are created equal, though. It’s better to stick to paper-filtered or instant coffee, because unfiltered types like espresso or French-press coffee retain cafestol, a natural compound associated with higher levels of “bad” cholesterol. It should also go without saying that adding heaps of cream, sugar, sweeteners or flavored syrups can offset any benefits. But, hey, it’s a great day for pour-over-drinking hipsters and beat officers everywhere.

Photo of people at the Moonshot AI Kimi booth at the World AI Conference.

It’s another DeepSeek moment, but with double the pain.

Chinese AI firm Moonshot lived up to its name on Friday with the launch of its ultra-powerful Kimi K3, a model rivaling America’s best even without access to America’s top semiconductors. By Monday, fellow Chinese company Alibaba had unveiled a similarly leading-edge model of its own. The one-two punch has rattled an industry starting to ponder its own affordability, though news out of Google shows Silicon Valley isn’t entirely caught on the back foot.

Model Citizens

Debuted at the World AI Conference in Shanghai on Friday last week, the latest Kimi model outperformed all rivals outside of Anthropic’s Claude Fable 5 and OpenAI’s GPT-5.6, according to most industry metrics. Until Monday, at least, when Alibaba unveiled the preview version of its Qwen3.8 Max model, which it claims is more powerful than both the flagship Moonshot and OpenAI models. Unlike Claude and GPT, the Kimi model is open-source while the Alibaba model is open-weight (meaning third-party developers can download it and tweak it, like open-source models, though they won’t have access to the original source code). Both were trained without the most expensive chips and are expected to be cheaper and more efficient to operate.

That’s obviously a problem for the US firms. As Anthropic and OpenAI speed toward IPOs, IG market analyst Tony Sycamore told Bloomberg on Monday that a combined $314 billion had been erased from Anthropic’s and OpenAI’s valuation estimates. For consumers and enterprise clients, the Chinese competitors look more and more enticing:

  • According to a Citi note shared with clients last month, Chinese AI firms are charging as little as $0.18 per million tokens, compared with an average of $4 per million tokens among US firms. That comes as only 5% of companies say their AI spending came in under budget, according to a McKinsey study published on Sunday, with 46% of firms saying their spending went over budget by as much as 30%.
  • Usage of Chinese models is unsurprisingly surging in the US. Nearly half of all US company tokens are now going toward Chinese models, according to OpenRouter data, up from a roughly 11% market share at the start of the year.

Gemini Season: Not for nothing, The Information reported on Monday that Google is developing a chip that could significantly optimize its Gemini AI model. The new chip likely won’t be deployed until at least 2028, sources told The Information, but shares of Google’s parent, Alphabet, jumped 1.5% anyway on Monday. The company’s next earnings call is on Wednesday, and affordability and AI spending will surely be top of mind.

Written by Brian Boyle

Photo via Cytonics

If you watched enough matches, you saw it: A star player went down clutching a knee, and everyone held their breath.

Most get back up. But the sport leaves a mark that outlasts the final whistle: retired footballers develop knee osteoarthritis at 2 to 3 times the rate of the general male population1.

Cytonics is out to change that math with what could be osteoarthritis’ first and only potential cure. Their first-generation therapy, engineered from the body’s cartilage-protecting protein, has already treated 10,000+ patients. Now Cytonics is pushing a mass-producible version toward FDA approval, in a $560B market that has never had a real solution.

Don’t wait to become an early-stage Cytonics shareholder: These are the final days to invest.*

The Farnborough International Airshow is held biennially in even years, leaving the odd years to the Paris Air Show because nothing rivals a week in the City of Light like spending one in a Hampshire town full of chain pubs.

To kick off the week, it’s typical for the world’s two largest commercial aircraft manufacturers, America’s Boeing and Europe’s Airbus, to make a show of dealmaking force. On Monday, they did not disappoint, but it was a pair of smaller firms with an electric twist that generated the most buzz.

Charging Up eVTOLs

The aviation duopoly’s annual flex went off as expected. Boeing secured an order of 100 737 Max planes from Ireland-based aircraft leasing company SMBC Aviation Capital, a subsidiary of Japanese conglomerate Sumitomo. The Virginia-headquartered aviation giant also notched commitments from Riyadh Air to buy 28 Boeing 787 Dreamliner jets and from Philippine Airlines to buy up to 20. Not to be outdone, Airbus won an order for 100 of its A320neo family aircraft, and Riyadh Air tacked on six additional Airbus A350-1000 aircraft to an order for 25 placed last year.

Airbus led in deliveries last month, while Boeing led in new orders, but the two have years of backlog to fulfill, making them strategic long-term holds in many portfolios. Airbus estimates annual global passenger traffic will more than double over the next 20 years to 10 billion, with the annual growth rate of 3.9% creating demand for over 42,000 aircraft in that time. And, while Farnborough’s first day backed up that projection, it also offered a glimpse into aviation’s future:

  • GE Aerospace, NASA and eVTOL-maker Beta Technologies said they successfully carried out the world’s first high-altitude flight using hybrid-electric propulsion. After they outfitted a Saab 340B commuter plane with a hybrid electric system, their pilots reached above 30,000 feet and flew for over two hours.
  • Electric air taxi firm Archer unveiled a hybrid-electric eVTOL jointly developed with buzzy defense startup Anduril for commercial and military use. With significant speed, range and endurance, the so-called Thunder can be a cargo vehicle or an “autonomous attack rotorcraft.”

Defensive Posture: Defense was front of mind, and in more immediate ways than robotaxis-turned-military-attack-rotorcraft. Lockheed Martin announced a lower-cost Patriot interceptor missile Monday, slated for production with fewer components in 2028, that could more than halve the $4 million price tag of the original model. Meanwhile, European missile company MBDA announced a rival low-cost interceptor system specifically designed to counter high-volume attacks by cheap munitions like drones, a tactic that’s been used to deplete enemy stockpiles.

Written by Sean Craig

Photo via Cytonics

Cytonics could hold osteoarthritis’s first potential cure in a $560B+ market that Big Pharma hasn’t cracked. Their first-gen therapy has already treated 10,000+ patients, and now they’re pushing a mass-producible version. Join 7,500+ investors as a shareholder, but hurry: These are the last days to invest.*

Photo of an Imax 70mm poster for The Odyssey.

The movie theater industry could finally be returning to friendly shores after seven years at sea. Shares of AMC Entertainment popped more than 20% Monday after the largest US theater chain posted double-digit revenue growth for the second quarter.

CEO Adam Aron called it the box office’s biggest quarter in seven years and thinks both domestic and global movie theaters are on track to have their strongest year since before the pandemic. Blockbusters including Toy Story 5 and The Super Mario Galaxy Movie boosted results for the spring quarter as Hollywood looked ahead to more grown-up flicks.

Despite being rated R, The Odyssey garnered the year’s third-largest opening weekend take. The epic film prompted cinephiles to flock to IMAX screens, in particular, showing they will pay a premium to see 40% more of Agamemnon’s helmet plume.

Wanted: IMAX Camera Popcorn Bucket

The Odyssey is the first feature film to be shot 100% on IMAX cameras, and AMC’s marketing team leaned into it. Director Christopher Nolan proved the format was popular with the 2023 hit Oppenheimer, which grossed nearly $180 million for IMAX in the fall quarter of that year. Nolan’s championing of the format is Trojan-horsing it into the mainstream:

  • In its opening weekend, The Odyssey took home nearly $30 million domestically and $52 million globally on IMAX’s ~1,900 screens, a record for the entertainment-tech company.
  • The limited number of IMAX screens has created competition in Hollywood. Dune 3 and Avengers: Doomsday are slated for the same release day later this year, December 18, and Denis Villeneuve’s sci-fi epic will have three weeks of IMAX exclusivity. Instead of backing off the winter holiday weekend, Disney announced Avengers: Doomsday will be shown on its own big-screen IMAX rival, called Infinity Vision.

Athena, WYA: Theaters are racing to add more IMAX screens, but it’s not an easy undertaking. AMC expanded its partnership with IMAX last year to add 12 new locations and upgrade 68 existing ones, IMAX’s largest deal since 2018. For the coveted 70mm experience, IMAX has said upgrading theaters is costly from a construction perspective and technologically difficult since most theaters are digital.

Written by Jamie Wilde

Extra Upside
  • Press Pause: The Paramount-Warner Bros. Discovery merger is on hold for at least two weeks after a California judge issued a temporary restraining order in a lawsuit by states seeking to block the deal.
  • Foodborne Fear: The FDA stands by its advisory against eating Taylor Farms lettuce but retracted its statement that a sample tested positive for cyclospora, the culprit in a foodborne illness outbreak.
  • Which Stocks Could Shape H2? Seeking Alpha’s Quant System just identified its next 10 high-conviction picks. The same model’s H1 2026 list is already up 70% so far this year, leaving the S&P 500’s 8% return in the rearview mirror. Read the full report.**

**Partner

Disclaimers

*This is a paid advertisement for Cytonics Regulation CF offering. Please read the offering circular at https://cytonics.com/.

Forward-looking statements are subject to risks and uncertainties. There is no guarantee of performance. Past performance does not predict future results. All investments involve risk, including loss of principal.

1Source: PubMed Central.

**Past performance is no guarantee for future results.

 

No longer want to receive these newsletters?
Unsubscribe here.

55 Union Place, #253
Summit, NJ 07901

Copyright © 2026 The Daily Upside, LLC
All rights reserved.

 
 

No comments:

Post a Comment